These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1221 related articles for article (PubMed ID: 22370313)

  • 1. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
    Sowa PM; Downes MJ; Gordon LG
    J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Johnson JM
    Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
    Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
    Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
    Logman JFS; Heeg BMS; Botteman MF; Kaura S; van Hout BA
    Ann Oncol; 2010 Jul; 21(7):1529-1536. PubMed ID: 19955334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?
    Dhesy-Thind SK
    J Clin Oncol; 2012 May; 30(13):1408-10. PubMed ID: 22370320
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy.
    Schousboe JT; Bauer DC; Nyman JA; Kane RL; Melton LJ; Ensrud KE
    Osteoporos Int; 2007 Feb; 18(2):201-10. PubMed ID: 17019515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
    JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is treatment of early postmenopausal women with bisphosphonates justified?
    Epstein S
    Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
    Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
    Mueller D; Gandjour A
    Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.